Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario

Organogenesis Holdings (ORGO) is focused on advanced wound-care and surgical biologics, with a Phase 3 trial for ReNu knee-osteoarthritis expected to yield data by September 2025, potentially unlocking the injectable OA market. The implementation of the CMS skin-substitute LCD has been postponed to January 2026, which could present a near-term headwind requiring more robust evidence for insurance reimbursements, but is expected to strengthen ORGO's position long term. The author views ORGO's valuation as compelling and rates the stock a "Buy" for long-term investors.

Analysis

Organogenesis Holdings Inc. (ORGO) is a regenerative medicine company whose primary growth drivers are its advanced wound-care and surgical biologics, supported by a robust evidence-generation strategy. A significant catalyst for the company is its Phase 3 trial for ReNu, a knee-osteoarthritis treatment, with pivotal data anticipated by September 2025, which could lead to a Biologics License Application (BLA) filing and access to the injectable osteoarthritis market. Regulatory developments include the postponement of the new Centers for Medicare & Medicaid Services (CMS) skin-substitute Local Coverage Determination (LCD) to January 2026. While this delay, requiring more substantial evidence for insurance reimbursements, may present a near-term headwind, ORGO's strong evidence portfolio is expected to strengthen its competitive position once the new LCD takes effect. The analyst commentary suggests that ORGO's current valuation appears compelling for long-term investors.

Key Decisions for Investors

• Investors with a long-term horizon may find Organogenesis Holdings' current valuation attractive, particularly considering the potential market expansion from its ReNu product candidate and its anticipated stronger positioning post-LCD implementation.
• Closely monitor the ReNu Phase 3 trial results, expected by September 2025, as this is a key potential value inflection point for the company.
• Acknowledge the potential for near-term market pressure or operational adjustments as the company navigates the period leading up to the new CMS skin-substitute LCD implementation in January 2026.